All T2D study subjects underwent evaluation of NAFLD and liver fibrosis through non-invasive methods, e.g., the measurements of serum ALT/AST and γ-GT, the calculation of FIB-4 score and the evaluation of liver stiffness through liver elastography, performed by FibroScan with controlled attenuation-parameter (CAP), for the quantification of intrahepatic fat [30,31]. The gene discussed is GPT; the disease is type 2 diabetes mellitus.